Can hepatic steatosis make fibrosis staging less accurate in chronic hepatitis B?

Hepatic steatosis (fatty liver) is common in people with chronic hepatitis B (CHB), affecting up to 33% of patients in some studies ⁹. Doctors often use blood-based scores like APRI (aspartate aminotransferase-to-platelet ratio index) and FIB-4 (fibrosis-4 index) to estimate liver fibrosis (scarring) without a biopsy. However, when a patient also has hepatic steatosis, these noninvasive tests may become much less reliable. Research shows that steatosis can severely impair the diagnostic accuracy of APRI and FIB-4, especially in those with moderate-to-severe fatty liver ⁵.

What the research says

A 2025 study specifically looked at how hepatic steatosis affects APRI and FIB-4 in treatment-naïve CHB patients who had a liver biopsy ⁵. In patients without steatosis, both APRI and FIB-4 performed well for detecting advanced fibrosis (Metavir stage F3-F4), with area under the receiver operating characteristic curve (AUROC) values of 0.896 and 0.854, respectively. But in patients with moderate-to-severe steatosis (grades S2-S3), the AUROC dropped dramatically to 0.473 for APRI and 0.468 for FIB-4, meaning these tests were no better than chance ⁵. The positive predictive value (PPV) of APRI fell from 73.1% in patients without steatosis to just 23.3% in those with steatosis, indicating a high rate of false positives ⁵.

Another study examined how liver fibrosis itself can affect the measurement of steatosis using the controlled attenuation parameter (CAP) on transient elastography ⁷. In 399 CHB patients, CAP correlated moderately with the actual amount of fat in the liver (r=0.445). However, the accuracy of CAP for diagnosing significant steatosis (≥10% fat) was lower in patients with advanced fibrosis (F2-F4) compared to those with mild or no fibrosis (F0-F1) ⁷. This suggests that fibrosis and steatosis can interfere with each other's noninvasive assessment.

Hepatic steatosis is common in CHB, with prevalence increasing over time and linked to metabolic factors like higher body mass index (BMI), blood sugar, and cholesterol ⁸⁹. In one large biopsy study, 13.6% of CHB patients had steatosis, and those with steatosis had lower HBV DNA levels, possibly due to metabolic interactions ⁸. Another study found steatosis in 33.4% of patients, with similar metabolic associations ⁹. These findings highlight that steatosis is a frequent comorbidity that can complicate fibrosis staging.

What to ask your doctor

• Do I have hepatic steatosis (fatty liver) in addition to chronic hepatitis B?
• If I have steatosis, are noninvasive fibrosis tests like APRI or FIB-4 still reliable for me?
• Should I consider a liver biopsy or another imaging method (like transient elastography) to get a more accurate fibrosis stage?
• What lifestyle changes (diet, exercise, weight loss) might help reduce steatosis and improve liver health?
• How often should I be monitored for liver fibrosis progression given my steatosis?